title: Optimizing the management of HER2-positive early breast cancer: the clinical reality.
abstract: Breast cancer positive for HER2 (human epidermal growth factor receptor 2) is associated with a poor prognosis for patients with both early-stage and metastatic breast cancer. Trastuzumab has been shown to be effective and is now considered the standard of care for early-stage patients with HER2-positive breast cancer. In that population, trastuzumab has been studied in six randomized clinical trials. Overall, use of this agent leads to a significant reduction in risk of disease recurrence and improvement in overall survival. Despite the strong evidence for the use of trastuzumab in managing HER2-positive early breast cancer (EBC), a number of clinical controversies remain. The authors of this paper undertook a review of the available scientific literature on adjuvant trastuzumab to produce practical considerations from Canadian oncologists. The panel focused their discussion on five key areas: Management of node-negative disease with tumours 1 cm or smaller in size. Management of HER2-positive EBC across the spectrum of the disease (that is, nodal and steroid hormone receptor status, tumour size) Timing of trastuzumab therapy with chemotherapy for early-stage disease: concurrent or sequential. Treatment duration of trastuzumab for EBC. The role of non-anthracycline trastuzumab-based regimens.
authors.affiliation: University of Toronto, Toronto, ON. sunil.verma@sunnybrook.ca
authors.forename: Su
authors.initials: S
authors.lastname: Verma
authors.forename: S
authors.initials: S
authors.lastname: Lavasani
authors.forename: J
authors.initials: J
authors.lastname: Mackey
authors.forename: K
authors.initials: K
authors.lastname: Pritchard
authors.forename: M
authors.initials: M
authors.lastname: Clemons
authors.forename: S
authors.initials: S
authors.lastname: Dent
authors.forename: J
authors.initials: J
authors.lastname: Latreille
authors.forename: J
authors.initials: J
authors.lastname: Lemieux
authors.forename: L
authors.initials: L
authors.lastname: Provencher
authors.forename: Sh
authors.initials: Sh
authors.lastname: Verma
authors.forename: S
authors.initials: S
authors.lastname: Chia
authors.forename: B
authors.initials: B
authors.lastname: Wang
authors.forename: D
authors.initials: D
authors.lastname: Rayson